Regulatory
AbbVie’s Mavyret (glecaprevir/pibrentasvir) Receives FDA’s Approval for its Expanded Indication
Shots: The US FDA has granted approval to Mavyret for shortening the treatment duration from 12 to 8wks. in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes […]readmore